Refine
Has Fulltext
- yes (68)
Is part of the Bibliography
- yes (68)
Year of publication
- 2021 (68) (remove)
Document Type
- Journal article (50)
- Doctoral Thesis (18)
Keywords
- Herzinsuffizienz (4)
- adrenocortical carcinoma (4)
- atherosclerosis (4)
- echocardiography (3)
- inflammation (3)
- obesity (3)
- paraganglioma (3)
- pheochromocytoma (3)
- wall shear stress (3)
- CXCR4 (2)
- FGFR (2)
- Kernspintomografie (2)
- Roux-en-Y gastric bypass surgery (2)
- acute heart failure (2)
- aortic arch (2)
- hypercortisolism (2)
- liraglutide (2)
- machine learning (2)
- mortality (2)
- mouse (2)
- myocardial infarction (2)
- pulse wave velocity (2)
- therapeutic drug monitoring (2)
- 4D flow (1)
- 4D flow MRI (1)
- 7 T (1)
- 7T (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- ACM (1)
- ACTH (1)
- ALT (1)
- ARVC (1)
- ATRX (1)
- Adipositas (1)
- Aortenklappenersatz (1)
- Autoantikörper (1)
- B (1)
- B cells (1)
- Bowditcheffekt (1)
- Braune Fettzelle (1)
- CCR7 (1)
- CD4+ T-cells (1)
- CMR (1)
- COH29 (1)
- COVID-19 (1)
- CTNNB1 (1)
- CXCR7 (1)
- Calcium (1)
- Calcium-Aufnahme (1)
- Chemokinrezeptor (1)
- Cholesterol metabolism (1)
- Congestiv Heart Failure (1)
- Cushing-Syndrom (1)
- Cushing’s disease (1)
- Cushing’s syndrome (1)
- DSC2 (1)
- DSG2 (1)
- Diabetes mellitus Typ 2 (1)
- E/e’ (1)
- EMT (1)
- FGF-pathway (1)
- Fabry-Krankheit (1)
- Fettsucht (1)
- Force-frequency relation (1)
- Frequenzüberstimulation (1)
- Glucosephosphatdehydrogenase (1)
- Glucosestoffwechsel (1)
- Glukoseaufnahme (1)
- HFmrEF (1)
- HFpEF (1)
- HFrEF (1)
- Haut (1)
- Herzinfarkt (1)
- High risk prostate cancer (1)
- Hochrisiko Prostatakarzinom (1)
- Hypoadrenalismus (1)
- Hypoglykämie (1)
- Hämodialyse (1)
- IP3-Signaling (1)
- IP3-sponge (1)
- Immunantwort (1)
- Immunreaktion (1)
- Inositoltrisphosphat (1)
- Kardiale Dekompensation (1)
- LDL cholesterol (1)
- LMNA (1)
- LV dilatation (1)
- LVNC (1)
- Linksventrikuläre systolische Funktion (1)
- Long COVID (1)
- Lysosomale Speicherkrankheit (1)
- MRI (1)
- Maus (1)
- Mitochondrien (1)
- Mitochondrium (1)
- Mitofusin2 (1)
- Morbus Fabry (1)
- Muscle (1)
- Muskel (1)
- Myokardinfarkt (1)
- Myokarditis (1)
- NEC (1)
- NET (1)
- NOP10 (1)
- NR3C1 (1)
- NSG animals (1)
- Natrium-23 (1)
- Navigation (1)
- Nebennierenrindencarcinom (1)
- Nebennierenrindeninsuffizienz (1)
- Nicotinamid-N-Methyltransferase (1)
- PD-L1 (1)
- PPGL (1)
- PTA (1)
- PWV (1)
- PYY3-36 (1)
- Patientenschulungen (1)
- Patientenzufriedenheit (1)
- Pericardium (1)
- Perikard (1)
- Perikardiozentese (1)
- Perikardpunktion (1)
- Prognose (1)
- Prognostische Bedeutung (1)
- Prädiktoren (1)
- Punktion (1)
- RNA Expression (1)
- RNAScope (1)
- RNR (1)
- RRM2 (1)
- Recovery (1)
- SOAT (1)
- SOAT Inhibitoren (1)
- SR/Mitochondriales Feedback (1)
- Sars-CoV-2 (1)
- Skin (1)
- Sterol O-Acyltransferasen (1)
- Sterol-O-Acyl transferases (1)
- Subjektive Krankheitswahrnehmung (1)
- TAVI (1)
- TERT (1)
- Therapieadhärenz (1)
- Tiermodell (1)
- Transthorakale Echokardiographie (1)
- Treppenphänomen (1)
- Typ-2-Diabetes-mellitus (1)
- USP8 (1)
- Ultrahochfeldmagnetresonanztomographie (1)
- Ultraschall (1)
- Ultraschallgeführte Biopsie (1)
- Ultraschallgesteuert (1)
- WSS (1)
- Wandschubspannung (1)
- Weiße Fettzelle (1)
- Zucker fatty fa/fa rats (1)
- [18F]FDG-PET-CT (1)
- abdominal lymph node metastases (1)
- adaptive immune response (1)
- adjuvant platinum-based chemotherapy (1)
- adjuvant treatment (1)
- adrenal (1)
- adrenal gland (1)
- adrenal tumors (1)
- adrenocortical cancer (1)
- adrenocortical cell line (1)
- adrenocortical tissues (1)
- adrenocortical tumors (1)
- afatinib (1)
- aneurysm (1)
- anti-myocardial (1)
- antibiotic prescription (1)
- antibodies (1)
- antimicrobial resistance (1)
- antimicrobial stewardship (1)
- anxiety (1)
- aortic valve disease percutaneous intervention (AVDP) (1)
- arrhythmia (1)
- arterial elasticity (1)
- arterial stiffening (1)
- autoantibody (1)
- behavior (1)
- biocompatibility (1)
- bioinformatic clustering (1)
- biomarker (1)
- biomarker prediction (1)
- body mass index (1)
- calcification (1)
- cardiac MRI (1)
- cardiac function (1)
- cardiac magnetic resonance (1)
- cardiomyopathy (1)
- cardiovascular diseases (1)
- cardiovascular magnetic resonance (1)
- carotid artery disease (1)
- catecholamines (1)
- chemokine receptor (1)
- chronic heart failure (1)
- chronotype (1)
- circadian rhythms (1)
- clinical data warehouse (1)
- clinical study (1)
- clonal hematopoiesis of indeterminate potential (1)
- closure AV fistula/AVM (CLAV) (1)
- color-coded (1)
- cortisol (1)
- cortisol-producing adenoma (1)
- cushing's syndrome (1)
- deep learning (1)
- depression (1)
- desmin (1)
- desmocollin-2 (1)
- desmoglein-2 (1)
- desmosomes (1)
- diagnostic (1)
- diastolic dysfunction (1)
- diastolic function (1)
- diet (1)
- digital phenotyping (1)
- digital subtraction angiography (1)
- dilated cardiomyopathy (1)
- ecological momentary assessment (1)
- eculizumab (1)
- electromagnetic tracking system (1)
- electronic data capture (1)
- electronic health records (1)
- electrophysiology (1)
- elektromagnetisches Trackingsystem (1)
- endovascular (1)
- energy homeostasis (1)
- epidemiology (1)
- epithelial markers (1)
- fatty liver (1)
- feature selection (1)
- flow (1)
- flow dynamics (1)
- fractionation membranev (1)
- gastric bypass (1)
- genetic analysis (1)
- glucocorticoid excess (1)
- glucose homeostasis (1)
- haemodialysis (1)
- heart failure (1)
- heart failure with mid-range ejection fraction (1)
- heart failure with reduced ejection fraction (1)
- hypercholesterolemia (1)
- hypothalamic gene expression (1)
- iPSC-CMs (1)
- imaging TTE/TEE (ITTE) (1)
- immune check inhibitor (1)
- immune checkpoint inhibitor (ICI) (1)
- immunohistochemistry (1)
- immunosenescence (1)
- immunotherapy (1)
- in silico analysis (1)
- inappropriate prescription (1)
- inebilizumab (1)
- inflammaging (1)
- internal medicine (1)
- kinase inhibitors (1)
- left ventricular ejection fraction (1)
- left ventricular geometric abnormality (1)
- left ventricular geometry (1)
- left ventricular mass (1)
- left ventricular remodeling (1)
- left ventricular thrombusv (1)
- leptin system (1)
- lifestyle (1)
- lipoprotein apheresis (1)
- lipoprotein(a) (1)
- liquid chromatography tandem mass spectrometry (LC-MS/MS (1)
- longitudinal studies (1)
- lymphocytes (1)
- magnetic resonance imaging (1)
- mapping (1)
- mass spectronomy (1)
- medicine (1)
- menopause (1)
- mesenchymal markers (1)
- miR-182-5p (1)
- miR-183 cluster (1)
- miRNA (1)
- mice (1)
- microscopy (1)
- mitotane (1)
- mobile crowdsensing (1)
- mobile health (1)
- molecular diagnostics (1)
- morbidity (1)
- mouse models (1)
- mutation triggers (1)
- mutations (1)
- myocardial aging (1)
- myocardial work (1)
- myocardial work efficiency (1)
- natriuretic peptide (1)
- neural networks (1)
- neurological (1)
- neurological complications (1)
- neuromyelitis optica spectrum disorders (1)
- normal adrenal glands (1)
- on-site examination (1)
- osimertinib (1)
- parathyroid carcinoma (1)
- patient survival (1)
- pediatric adrenocortical adenoma (1)
- pediatric adrenocortical cancer (1)
- pediatric adrenocortical tumor (1)
- pembrolizumab (1)
- peptide tyrosine tyrosine (PYY) (1)
- peptide tyrosine tyrosine 3-36 (PYY3-36) (1)
- percutaneous valve therapy (PVT) (1)
- pericardiocentesis (1)
- personalized antimicrobial therapy (1)
- pharmacoepidemiology (1)
- phosphorylation (1)
- physical activity (1)
- piperacillin/tazobactam (1)
- plaque (1)
- plaque characteristics (1)
- population-based (1)
- primary healthcare (1)
- prognosis (1)
- prognostic (1)
- prognostic biomarker (1)
- prognostic factors (1)
- protein kinase a (1)
- quantification (1)
- radial (1)
- radical resection (1)
- ravulizumab (1)
- recovery (1)
- recurrence (1)
- recurrence free survival (1)
- recurrence-free survival (1)
- refugee healthcare (1)
- renal artery (1)
- repeated surgery (1)
- right ventricular dysfunction (1)
- rygb (1)
- satralizumab (1)
- secondary data usage (1)
- segmentation (1)
- self-navigation (1)
- serotonin transporter deficient mice (1)
- shimming (1)
- signalling (1)
- smoking (1)
- sodium-23 (1)
- spironolactone (1)
- surveillance (1)
- targeted metabolomics (1)
- telomeres (1)
- therapy (1)
- timing (1)
- tocilizumab (1)
- transcatheter valveimplantation (TVI) (1)
- transfer learning (1)
- treatment (1)
- tumour (1)
- type 2 diabetes (1)
- tyrosine kinase inhibitor (TKI) (1)
- ublituximab (1)
- ultra highfield magnetic resonance imaging (1)
- ultrahigh field (1)
- ultrahigh-field (1)
- ultrasound guided (1)
- unsupervised clustering (1)
- viral infection (1)
Institute
- Medizinische Klinik und Poliklinik I (68) (remove)
Sonstige beteiligte Institutionen
Die häufigste Form der Herzinsuffizienz in Deutschland ist die dilatative Kardiomyopathie, wobei bei ca. 6/100.000 Einwohnern pro Jahr keine eindeutige Ursache erkennbar ist und somit eine idiopathische DCM diagnostiziert wird. Ein Faktor zur Entstehung einer idiopathischen DCM könnten Autoantikörper gegen den β1-adrenergen Rezeptor sein. Bei ca. 30% der Patienten, die an einer DCM (Äquivalent in der ETiCS-Studie: erste akute Myokarditis = AMitis) leiden, sowie bei ca. 13% der Patienten, die an einer ischämischen Kardiomyopathie (Äquivalent in der ETiCS-Studie: erster akuter Myokardinfarkt = FAMI) leiden, konnten in älteren Arbeiten β1-AAk nachgewiesen werden. Im Rahmen der ETiCS-Studie erfolgte erstmals eine prospektive Beobachtung entsprechender Patientenkollektive über 12 Monate mit Blutentnahme und klinischen Kontrollen zum Zeitpunkt 0 Monate (=Baseline), 2-3 Monate (Follow-Up 1), 6 Monate (FUP2) und 12 Monate (FUP3). Zu diesen Zeitpunkten wurden anhand der gewonnenen Blutproben der β1-AAk-Status sowie die immunologischen Marker der FAMI- und AMitis-Patienten bestimmt und mit der kardialen LV-Pumpfunktion korreliert.
Zentrales Thema dieser Arbeit war es, Zusammenhänge zwischen der β1-AAk-Ausbildung in Abhängigkeit von individuellen Zytokinprofilen und der Entwicklung der LV-Pumpfunktion nach dem jeweiligen kardialen Ereignis zu untersuchen, wobei FAMI- und AMitis-Patienten miteinander verglichen wurden. Darüber hinaus wurde auch der Einfluss der CTLA-4-Haplotypen, also die „genetische“ Suszeptibilität Autoantikörper zu entwickeln, untersucht.
Während bei FAMI-Patienten die Entwicklung von β1-AAk keinen Einfluss auf den Verlauf der LV-Pumpfunktion zu haben scheint, wird diese bei AMitis-Patienten durch hochaffine β1-AAk im Verlauf stark beeinträchtigt.
Bei FAMI-Patienten konnte nach einer größeren Herzschädigung (CK-Werte >1000 U/l) eine schlechtere Pumpfunktion im Vergleich zu kleineren Myokardinfarkten (CK-Werte <1000 U/l) nachgewiesen werden, unabhängig von β1-AAk-Status. Für die Prognose und die Erholung der LV-Pumpfunktion scheint bei FAMI-Patienten folglich die Infarktgröße, aber nicht die Entwicklung von β1-AAk wichtig zu sein.
Hinsichtlich der unterschiedlichen Zytokinprofile bei FAMI- und AMitis-Patienten, die hochaffine β1-AAk entwickeln, scheinen bestimmte Zytokine die Induktion einer kardialen Autoimmunität zu begünstigen, während andere Zytokine wohl eher protektive immunologische Reaktionen in Gang setzen: Die proinflammatorischen Zytokine IL-1β, IL-2, IL-7, IL-12, IL-17, GM-CSF, MIP-1α und IFN-γ waren bei β1-AAk-positiven AMitis-Patienten statistisch signifikant erhöht. Protektive Effekte könnten dagegen von den antiinflammatorischen Zytokinen IL-1RA, IL-10 und IL-13 ausgehen, deren Serumspiegel bei FAMI- gegenüber AMitis-Patienten im Vergleich erhöht waren.
Beim direkten Vergleich von AMitis-Patienten mit hochaffinen β1-AAk und solchen ohne β1-AAk, zeigten sich bei Patienten mit hochaffinen β1-AAk höhere Konzentrationen an IL-1β, IL-2, IL-6, IL-7, IL-12, IL-17, GM-CSF, MIP-1α und TNF-α. Bei Patienten ohne Autoantikörper waren demgegenüber die Spiegel von IL-1RA, IL-10 und IL-13 erhöht, was zu einer besseren Erholung der LV-Pumpfunktion führte.
Nach genetischer Typisierung der CTLA-4-Haplotypen (Polymorphismen SNP +49G/A und SNP CT60A/G) fand sich bei Patienten mit dem Allel G/G ein höheres Risiko β1-AAk zu entwickeln, während das Allel A/A jeweils mit einem geringeren Risiko kardiale Autoantikörper zu entwickeln assoziiert war und somit protektiv gegen Autoimmunphänomene wirken könnte.
A relevant issue on the treatment of adrenocortical carcinoma (ACC) concerns the optimal duration of adjuvant mitotane treatment. We tried to address this question, assessing whether a correlation exists between the duration of adjuvant mitotane treatment and recurrence-free survival (RFS) of patients with ACC. We conducted a multicenter retrospective analysis on 154 ACC patients treated for ≥12 months with adjuvant mitotane after radical surgery and who were free of disease at the mitotane stop. During a median follow-up of 38 months, 19 patients (12.3%) experienced recurrence. We calculated the RFS after mitotane (RFSAM), from the landmark time-point of mitotane discontinuation, to overcome immortal time bias. We found a wide variability in the duration of adjuvant mitotane treatment among different centers and also among patients cared for at the same center, reflecting heterogeneous practice. We did not find any survival advantage in patients treated for longer than 24 months. Moreover, the relationship between treatment duration and the frequency of ACC recurrence was not linear after stratifying our patients in tertiles of length of adjuvant treatment. In conclusion, the present findings do not support the concept that extending adjuvant mitotane treatment over two years is beneficial for ACC patients with low to moderate risk of recurrence.
Perikardpunktionen werden neben diagnostischen Anwendungen vor allem in Notfallsituationen, wie bei einer Perikardtamponade, eingesetzt und können dann lebensrettend sein. Unerfahrene Untersucher stellen hierbei aber einen wesent- lichen Faktor für Komplikationen oder den Behandlungserfolg dar.
Um die Perikardpunktion zu optimieren, wurde im Rahmen einer experimentellen Untersuchung die neue Technik unter Verwendung eines elektromagnetischen Nadel Tracking Systems validiert. Hierzu wurde zunächst ein Modell entwickelt um die Punktionsgenauigkeit des Systems abhängig von seinen Einflussgrößen möglichst exakt beurteilen zu können. Es zeigte sich, dass das Punktionsergebnis von mehreren Faktoren wie Punktionswinkel, -seite, Ultraschallebene, Abstand zum Ziel und Vorhandensein von Metallgegenständen abhängt.
Des Weiteren wurde ein realitätsnahes Perikardpunktionsmodell verwendet. An diesem Modell wurden Perikardergüsse unterschiedlicher Größe simuliert und anschließend Punktionen mit der Nadel durchgeführt. Im BluePhantomTM Modell wurden mithilfe des Nadel Tracking Systems von unerfahrenen Untersuchern Trefferquoten zwischen 80 und 100% erreicht, unabhängig von der Ergussgröße. Anatomisch orientierte Punktionen erreichten hingegen nur Trefferquoten zwischen 11 und 44% bei einer Ergussmenge von 250 ml (bzw. 60-80% bei 450 ml).
Das getestete Nadel Tracking System könnte somit zur Verbesserung der Perikardpunktionen beitragen. Für eine abschließende Bewertung ist eine Validierung der Methode unter klinischen Bedingungen möglich.
Prospective longitudinal follow‐up of left ventricular ejection fraction (LVEF) trajectories after acute cardiac decompensation of heart failure is lacking. We investigated changes in LVEF and covariates at 6‐months' follow‐up in patients with a predischarge LVEF ≤40%, and determined predictors and prognostic implications of LVEF changes through 18‐months' follow‐up.
Methods and Results
Interdisciplinary Network Heart Failure program participants (n=633) were categorized into subgroups based on LVEF at 6‐months' follow‐up: normalized LVEF (>50%; heart failure with normalized ejection fraction, n=147); midrange LVEF (41%–50%; heart failure with midrange ejection fraction, n=195), or persistently reduced LVEF (≤40%; heart failure with persistently reduced LVEF , n=291). All received guideline‐directed medical therapies. At 6‐months' follow‐up, compared with patients with heart failure with persistently reduced LVEF, heart failure with normalized LVEF or heart failure with midrange LVEF subgroups showed greater reductions in LV end‐diastolic/end‐systolic diameters (both P<0.001), and left atrial systolic diameter (P=0.002), more increased septal/posterior end‐diastolic wall‐thickness (both P<0.001), and significantly greater improvement in diastolic function, biomarkers, symptoms, and health status. Heart failure duration <1 year, female sex, higher predischarge blood pressure, and baseline LVEF were independent predictors of LVEF improvement. Mortality and event‐free survival rates were lower in patients with heart failure with normalized LVEF (P=0.002). Overall, LVEF increased further at 18‐months' follow‐up (P<0.001), while LV end‐diastolic diameter decreased (P=0.048). However, LVEF worsened (P=0.002) and LV end‐diastolic diameter increased (P=0.047) in patients with heart failure with normalized LVEF hospitalized between 6‐months' follow‐up and 18‐months' follow‐up.
Conclusions
Six‐month survivors of acute cardiac decompensation for systolic heart failure showed variable LVEF trajectories, with >50% showing improvements by ≥1 LVEF category. LVEF changes correlated with various parameters, suggesting multilevel reverse remodeling, were predictable from several baseline characteristics, and were associated with clinical outcomes at 18‐months' follow‐up. Repeat hospitalizations were associated with attenuation of reverse remodeling."
Background
Combination therapies of anorectic gut hormones partially mimic the beneficial effects of bariatric surgery. Thus far, the effects of a combined chronic systemic administration of Glucagon-like peptide-1 (GLP-1) and peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) have not been directly compared to Roux-en-Y gastric bypass (RYGB) in a standardized experimental setting.
Methods
High-fat diet (HFD)-induced obese male Wistar rats were randomized into six treatment groups: (1) RYGB, (2) sham-operation (shams), (3) liraglutide, (4) PYY\(_{3-36}\), (5) PYY\(_{3-36}\)+liraglutide (6), saline. Animals were kept on a free choice high- and low-fat diet. Food intake, preference, and body weight were measured daily for 4 weeks. Open field (OP) and elevated plus maze (EPM) tests were performed.
Results
RYGB reduced food intake and achieved sustained weight loss. Combined PYY\(_{3-36}\)+liraglutide treatment led to similar and plateaued weight loss compared to RYGB. Combined PYY\(_{3-36}\)+liraglutide treatment was superior to PYY\(_{3-36}\) (p ≤ 0.0001) and liraglutide (p ≤ 0.05 or p ≤ 0.01) mono-therapy. PYY\(_{3-36}\)+liraglutide treatment and RYGB also reduced overall food intake and (less pronounced) high-fat preference compared to controls. The animals showed no signs of abnormal behavior in OF or EPM.
Conclusions
Liraglutide and PYY\(_{3-36}\) combination therapy vastly mimics reduced food intake, food choice and weight reducing benefits of RYGB.
Chronotype is defined as the behavioral manifestation of circadian rhythms related to the external light–dark cycle. Evening chronotype has been associated with an increased risk of developing cardiometabolic diseases in obesity. Menopause is a lifestage associated with an increased risk of developing cardiometabolic diseases and a change in circadian rhythmicity compared to pre-menopause. However, the prevalence of chronotype categories in menopause and their role in determining menopause-related cardiometabolic risk, mostly in obesity, have not been investigated. Thus, we aimed to investigate the prevalence of chronotype categories in post-menopausal women with obesity and their role in menopause-related cardiometabolic risk. In this cross-sectional study we enrolled 49 pre-menopausal and 74 post-menopausal women with obesity. Anthropometric parameters, lifestyle habits, adherence to the Mediterranean Diet (MD), sleep quality, chronotype and the presence of type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVD) were studied. No significance differences were detected in terms of lifestyle and adherence to the MD between pre- and post-menopausal women. Chronotype was classified as morning in 66 (53.6%), evening in 20 (16.3%) and intermediate in 37 (30.1%) women. In addition, pre-menopausal women with obesity showed a significantly higher chance to have an intermediate chronotype (OR = 2.21, 95% CI 1.28–3.83; p = 0.004), whereas post-menopausal women with obesity showed a trend to have a higher morning chronotype (OR = 1.42, 95% CI 0.98–2.06; p = 0.051), although this did not reach statistical significance. No significant differences were detected in terms of prevalence of evening chronotype between the two groups. However, the evening chronotype had a significantly higher risk to have T2DM compared to the morning (OR = 17.29, 95% CI 2.40–124.27; p = 0.005) and intermediate chronotypes (OR = 30.86, 95% CI 2.05–464.32; p = 0.013) in both pre- and post-menopausal women with obesity. In conclusion, the intermediate chronotype was significantly more prevalent in pre-menopausal women with obesity compared to post-menopausal women. Evening chronotype was associated to T2DM in both pre- and post-menopause. These results support the importance of including the assessment of chronotype in the management of women with obesity in post-menopause.
Heart failure with preserved ejection fraction (HFpEF) is highly prevalent in patients on maintenance haemodialysis (HD) and lacks effective treatment. We investigated the effect of spironolactone on cardiac structure and function with a specific focus on diastolic function parameters. The MiREnDa trial examined the effect of 50 mg spironolactone once daily versus placebo on left ventricular mass index (LVMi) among 97 HD patients during 40 weeks of treatment. In this echocardiographic substudy, diastolic function was assessed using predefined structural and functional parameters including E/e'. Changes in the frequency of HFpEF were analysed using the comprehensive 'HFA-PEFF score'. Complete echocardiographic assessment was available in 65 individuals (59.5 ± 13.0 years, 21.5% female) with preserved left ventricular ejection fraction (LVEF > 50%). At baseline, mean E/e' was 15.2 ± 7.8 and 37 (56.9%) patients fulfilled the criteria of HFpEF according to the HFA-PEFF score. There was no significant difference in mean change of E/e' between the spironolactone group and the placebo group (+ 0.93 ± 5.39 vs. + 1.52 ± 5.94, p = 0.68) or in mean change of left atrial volume index (LAVi) (1.9 ± 12.3 ml/m\(^{2}\) vs. 1.7 ± 14.1 ml/m\(^{2}\), p = 0.89). Furthermore, spironolactone had no significant effect on mean change in LVMi (+ 0.8 ± 14.2 g/m\(^{2}\) vs. + 2.7 ± 15.9 g/m\(^{2}\); p = 0.72) or NT-proBNP (p = 0.96). Treatment with spironolactone did not alter HFA-PEFF score class compared with placebo (p = 0.63). Treatment with 50 mg of spironolactone for 40 weeks had no significant effect on diastolic function parameters in HD patients.
The cardiovascular and immune systems undergo profound and intertwined alterations with aging. Recent studies have reported that an accumulation of memory and terminally differentiated T cells in elderly subjects can fuel myocardial aging and boost the progression of heart diseases. Nevertheless, it remains unclear whether the immunological senescence profile is sufficient to cause age-related cardiac deterioration or merely acts as an amplifier of previous tissue-intrinsic damage. Herein, we sought to decompose the causality in this cardio-immune crosstalk by studying young mice harboring a senescent-like expanded CD4\(^+\) T cell compartment. Thus, immunodeficient NSG-DR1 mice expressing HLA-DRB1*01:01 were transplanted with human CD4\(^+\) T cells purified from matching donors that rapidly engrafted and expanded in the recipients without causing xenograft reactions. In the donor subjects, the CD4\(^+\) T cell compartment was primarily composed of naïve cells defined as CCR7\(^+\)CD45RO\(^-\). However, when transplanted into young lymphocyte-deficient mice, CD4\(^+\) T cells underwent homeostatic expansion, upregulated expression of PD-1 receptor and strongly shifted towards effector/memory (CCR7\(^-\) CD45RO\(^+\)) and terminally-differentiated phenotypes (CCR7\(^-\)CD45RO\(^-\)), as typically seen in elderly. Differentiated CD4\(^+\) T cells also infiltrated the myocardium of recipient mice at comparable levels to what is observed during physiological aging. In addition, young mice harboring an expanded CD4\(^+\) T cell compartment showed increased numbers of infiltrating monocytes, macrophages and dendritic cells in the heart. Bulk mRNA sequencing analyses further confirmed that expanding T-cells promote myocardial inflammaging, marked by a distinct age-related transcriptomic signature. Altogether, these data indicate that exaggerated CD4\(^+\) T-cell expansion and differentiation, a hallmark of the aging immune system, is sufficient to promote myocardial alterations compatible with inflammaging in juvenile healthy mice.
Rezente Studien mit kleineren Fallzahlen offenbaren bei Patienten mit chronischer Nebenniereninsuffizienz eine sehr negative Krankheitswahrnehmung, große Ängste und Sorgen hinsichtlich der Substitutionstherapie mit Glucocorticoiden sowie eine geringe Therapieadhärenz.
Ziel der vorliegenden Beobachtungsstudie war es daher im Rahmen einer monozentrischen Querschnittstudie nebenniereninsuffiziente Patienten zu Therapieadhärenz, subjektiver Krankheits- und Glucocorticoidwahrnehmung und Zufriedenheit mit erhaltenen Informationen zu befragen. Zudem wurden erstmalig die Zusammenhänge zwischen der Teilnahme an einer standardisierten NNI-Schulung und oben genannten Aspekten im Rahmen einer multizentrischen Längschnittstudie untersucht.
Die Ergebnisse der Querschnittstudie zeichnen insgesamt ein deutlich positiveres Bild von der subjektiven Krankheits- und Therapiewahrnehmung als bisher in der Literatur beschrieben. Die subjektive Therapieadhärenz war hoch. Zudem waren Sorgen und Ängste hinsichtlich der Glucocorticoid-Substitution geringer ausgeprägt als erwartet. Nichtsdestotrotz ließ sich konkordant zu früheren Publikationen eine zum Teil sehr große Unzufriedenheit mit erhaltenen Informationen zu möglichen Problemen der Glucocorticoid-Substitution feststellen. Die Ergebnisse der Längschnittstudie deuten darauf hin, dass die standardisierte Patientenschulung ein geeignetes Instrument sein könnte, um die Zufriedenheit von Patienten mit NNI zu steigern, das Selbstmanagement zu stärken und gleichzeitig positiven Einfluss auf die Wahrnehmung der Substitutionstherapie nehmen könnte.
Sterol O-Acyltransferasen (SOATs) spielen eine zentrale Rolle im Cholesterinstoffwechsel von Zellen, indem sie die Veresterung von freiem Cholesterin und Speicherung in Lipid droplets katalysieren. In Tumorzellen findet häufig eine Aktivierung alternativer Pfade des Energiestoffwechsels, unter anderem des Lipidstoffwechsels statt. Präklinische und klinische Daten unterstützen den Mechanismus der SOAT-Inhibierung als Therapiekonzept für bestimmte Tumore. Eine genaue Kenntnis sowohl dieser Inhibitoren als auch der Expression des Zielmoleküls ist Voraussetzung für eine klinische Anwendung.
Im ersten Teil dieser Arbeit wurde ein in-vitro SOAT-Aktivitätsassay etabliert und auf Grundlage dessen ein Vergleich der mittleren Hemmstärken ausgewählter SOAT-Inhibitoren gezogen. SOAT-transfizierte AD-293 Zellen sowie NCI-H295R Nebennieren-Zellen wurden mit dem fluoreszierenden 22-NBD-Cholesterin sowie den SOAT-Inhibitoren inkubiert und die Veresterung des Lipid-Analogons dann zunächst mikroskopisch und anschließend quantitativ mittels chromatographischer Auftrennung untersucht. Mitotane stellte sich mit einer IC50 von 1,3x10⁻⁶ M als schwächster SOAT-Inhibitor dar, gefolgt von Sandoz58-035 (IC50=1,4x10\(^{-8}\) M), ATR101 (IC50=3,1x10\(^{-9}\) M) und schließlich AZD3988 (IC50=8,8x10\(^{-10}\) M).
Im zweiten Teil dieser Arbeit wurde die SOAT-Expression in Prostatektomiepräparaten von Hochrisiko Prostatakarzinom-Patienten mittels Immunhistochemie bestimmt. Eine starke SOAT1 Expression (SOAT H-Score 3) war sowohl in der univariaten als auch in der multivariaten Analyse hoch signifikant mit einem kürzeren biochemisch progressfreien Überleben der Patienten assoziiert unabhängig von etablierten Prognoseparametern [HR für den biochemischen Progress 2,33 (95%KI 1,48-3,68), p<0,001)]. Für SOAT2 war dies erwartungsgemäß nicht der Fall. SOAT1 scheint bei diesem bestimmten Kollektiv einen vielversprechenden Stellenwert als prognostischer Marker zu haben und könnte darüber hinaus zukünftig als Zielmolekül im Rahmen einer individualisierten Therapie des Prostatakarzinoms in Frage kommen.
Simultaneous measurements of 3D wall shear stress and pulse wave velocity in the murine aortic arch
(2021)
Purpose
Wall shear stress (WSS) and pulse wave velocity (PWV) are important parameters to characterize blood flow in the vessel wall. Their quantification with flow-sensitive phase-contrast (PC) cardiovascular magnetic resonance (CMR), however, is time-consuming. Furthermore, the measurement of WSS requires high spatial resolution, whereas high temporal resolution is necessary for PWV measurements. For these reasons, PWV and WSS are challenging to measure in one CMR session, making it difficult to directly compare these parameters. By using a retrospective approach with a flexible reconstruction framework, we here aimed to simultaneously assess both PWV and WSS in the murine aortic arch from the same 4D flow measurement.
Methods
Flow was measured in the aortic arch of 18-week-old wildtype (n = 5) and ApoE\(^{−/−}\) mice (n = 5) with a self-navigated radial 4D-PC-CMR sequence. Retrospective data analysis was used to reconstruct the same dataset either at low spatial and high temporal resolution (PWV analysis) or high spatial and low temporal resolution (WSS analysis). To assess WSS, the aortic lumen was labeled by semi-automatically segmenting the reconstruction with high spatial resolution. WSS was determined from the spatial velocity gradients at the lumen surface. For calculation of the PWV, segmentation data was interpolated along the temporal dimension. Subsequently, PWV was quantified from the through-plane flow data using the multiple-points transit-time method. Reconstructions with varying frame rates and spatial resolutions were performed to investigate the influence of spatiotemporal resolution on the PWV and WSS quantification.
Results
4D flow measurements were conducted in an acquisition time of only 35 min. Increased peak flow and peak WSS values and lower errors in PWV estimation were observed in the reconstructions with high temporal resolution. Aortic PWV was significantly increased in ApoE\(^{−/−}\) mice compared to the control group (1.7 ± 0.2 versus 2.6 ± 0.2 m/s, p < 0.001). Mean WSS magnitude values averaged over the aortic arch were (1.17 ± 0.07) N/m\(^2\) in wildtype mice and (1.27 ± 0.10) N/m\(^2\) in ApoE\(^{−/−}\) mice.
Conclusion
The post processing algorithm using the flexible reconstruction framework developed in this study permitted quantification of global PWV and 3D-WSS in a single acquisition. The possibility to assess both parameters in only 35 min will markedly improve the analyses and information content of in vivo measurements.
Background: The hypothalamus is an important brain region for the regulation of energy balance. Roux-en-Y gastric bypass (RYGB) surgery and gut hormone-based treatments are known to reduce body weight, but their effects on hypothalamic gene expression and signaling pathways are poorly studied. Methods: Diet-induced obese male Wistar rats were randomized into the following groups: RYGB, sham operation, sham + body weight-matched (BWM) to the RYGB group, osmotic minipump delivering PYY3-36 (0.1 mg/kg/day), liraglutide s.c. (0.4 mg/kg/day), PYY3-36 + liraglutide, and saline. All groups (except BWM) were kept on a free choice of high- and low-fat diets. Four weeks after interventions, hypothalami were collected for RNA sequencing. Results: While rats in the RYGB, BWM, and PYY3-36 + liraglutide groups had comparable reductions in body weight, only RYGB and BWM treatment had a major impact on hypothalamic gene expression. In these groups, hypothalamic leptin receptor expression as well as the JAK–STAT, PI3K-Akt, and AMPK signaling pathways were upregulated. No significant changes could be detected in PYY3-36 + liraglutide-, liraglutide-, and PYY-treated groups. Conclusions: Despite causing similar body weight changes compared to RYGB and BWM, PYY3-36 + liraglutide treatment does not impact hypothalamic gene expression. Whether this striking difference is favorable or unfavorable to metabolic health in the long term requires further investigation.
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy and treatment of advanced disease is challenging. Clinical trials with multi-tyrosine kinase inhibitors in the past have yielded disappointing results. Here, we investigated fibroblast growth factor (FGF) receptors and their pathways in adrenocortical tumors as potential treatment targets. We performed real-time RT-PCR of 93 FGF pathway related genes in a cohort of 39 fresh frozen benign and malignant adrenocortical, 9 non-adrenal tissues and 4 cell lines. The expression of FGF receptors was validated in 166 formalin-fixed paraffin embedded (FFPE) tissues using RNA in situ hybridization (RNAscope) and correlated with clinical data. In malignant compared to benign adrenal tumors, we found significant differences in the expression of 16/94 FGF receptor pathway related genes. Genes involved in tissue differentiation and metastatic spread through epithelial to mesechymal transition were most strongly altered. The therapeutically targetable FGF receptors 1 and 4 were upregulated 4.6- and 6-fold, respectively, in malignant compared to benign adrenocortical tumors, which was confirmed by RNAscope in FFPE samples. High expression of FGFR1 and 4 was significantly associated with worse patient prognosis in univariate analysis. After multivariate adjustment for the known prognostic factors Ki-67 and ENSAT tumor stage, FGFR1 remained significantly associated with recurrence-free survival (HR=6.10, 95%CI: 1.78 – 20.86, p=0.004) and FGFR4 with overall survival (HR=3.23, 95%CI: 1.52 – 6.88, p=0.002). Collectively, our study supports a role of FGF pathways in malignant adrenocortical tumors. Quantification of FGF receptors may enable a stratification of ACC for the use of FGFR inhibitors in future clinical trials.
Purpose
Unnecessary and inappropriate use of antibiotics is a widespread problem in primary care. However, current data on the care of refugees and migrants in initial reception centers is pending. This article provides data on prescription frequencies of various antibiotics and associated diagnoses.
Methods
In this retrospective observational study, patient data of 3255 patients with 6376 medical contacts in two initial reception centers in Germany were analyzed. Patient data, collected by chart review, included sociodemographic characteristics, diagnoses, and prescriptions. Antibiotic prescription behavior and corresponding physician‐coded diagnoses were analyzed.
Results
Nineteen percent of all patients in our study received systemic antibiotics during the observation period, with children below the age of 10 years receiving antibiotics most frequently (24%). The most commonly prescribed antibiotics were penicillins (65%), macrolides (12%), and cephalosporins (7%). The most frequent diagnoses associated with antibiotic prescription were acute tonsillitis (26%), bronchitis (21%), infections of the upper respiratory tract (14%), and urinary tract infections (10%). In case of acute bronchitis 74% of the antibiotic prescriptions were probably not indicated. In addition, we found a significant number of inappropriate prescriptions such as amoxicillin for tonsillitis (67%), and ciprofloxacin and cotrimoxazol for urinary tract infections (49%).
Conclusion
Regarding inappropriate prescription of antibiotics in refugee healthcare, this study shows a rate ranging from 8% for upper respiratory tract infections to 75% for acute bronchitis. Unnecessary use of antibiotics is a global problem contributing to gratuitous costs, side effects, and antimicrobial resistance. This research contributes to the development of stringent antibiotic stewardship regiments in the particularly vulnerable population of migrants and refugees.
Context
Pheochromocytomas and paragangliomas (PPGL) cause catecholamine excess leading to a characteristic clinical phenotype. Intra-individual changes at metabolome level have been described after surgical PPGL removal. The value of metabolomics for the diagnosis of PPGL has not been studied yet.
Objective
Evaluation of quantitative metabolomics as a diagnostic tool for PPGL.
Design
Targeted metabolomics by liquid chromatography-tandem mass spectrometry of plasma specimens and statistical modeling using ML-based feature selection approaches in a clinically well characterized cohort study.
Patients
Prospectively enrolled patients (n=36, 17 female) from the Prospective Monoamine-producing Tumor Study (PMT) with hormonally active PPGL and 36 matched controls in whom PPGL was rigorously excluded.
Results
Among 188 measured metabolites, only without considering false discovery rate, 4 exhibited statistically significant differences between patients with PPGL and controls (histidine p=0.004, threonine p=0.008, lyso PC a C28:0 p=0.044, sum of hexoses p=0.018). Weak, but significant correlations for histidine, threonine and lyso PC a C28:0 with total urine catecholamine levels were identified. Only the sum of hexoses (reflecting glucose) showed significant correlations with plasma metanephrines.
By using ML-based feature selection approaches, we identified diagnostic signatures which all exhibited low accuracy and sensitivity. The best predictive value (sensitivity 87.5%, accuracy 67.3%) was obtained by using Gradient Boosting Machine Modelling.
Conclusions
The diabetogenic effect of catecholamine excess dominates the plasma metabolome in PPGL patients. While curative surgery for PPGL led to normalization of catecholamine-induced alterations of metabolomics in individual patients, plasma metabolomics are not useful for diagnostic purposes, most likely due to inter-individual variability.
Mutations in the PRKACA gene are the most frequent cause of cortisol-producing adrenocortical adenomas leading to Cushing’s syndrome. PRKACA encodes for the catalytic subunit α of protein kinase A (PKA). We already showed that PRKACA mutations lead to impairment of regulatory (R) subunit binding. Furthermore, PRKACA mutations are associated with reduced RIIβ protein levels; however, the mechanisms leading to reduced RIIβ levels are presently unknown. Here, we investigate the effects of the most frequent PRKACA mutation, L206R, on regulatory subunit stability. We find that Ser\(^{114}\) phosphorylation of RIIβ is required for its degradation, mediated by caspase 16. Last, we show that the resulting reduction in RIIβ protein levels leads to increased cortisol secretion in adrenocortical cells. These findings reveal the molecular mechanisms and pathophysiological relevance of the R subunit degradation caused by PRKACA mutations, adding another dimension to the deregulation of PKA signaling caused by PRKACA mutations in adrenal Cushing’s syndrome.
Therapeutic drug monitoring (TDM) is increasingly relevant for an individualized antibiotic therapy and subsequently a necessary tool to reduce multidrug-resistant pathogens, especially in light of diminishing antimicrobial capabilities. Critical illness is associated with profound pharmacokinetic and pharmacodynamic alterations, which challenge dose finding and the application of particularly hydrophilic drugs such as β-lactam antibiotics. Methods: Implementation strategy, potential benefit, and practicability of the developed standard operating procedures were retrospectively analyzed from January to December 2020. Furthermore, the efficacy of the proposed dosing target of piperacillin in critically ill patients was evaluated. Results: In total, 160 patients received piperacillin/tazobactam therapy and were subsequently included in the study. Of them, 114 patients received piperacillin/tazobactam by continuous infusion and had at least one measurement of piperacillin serum level according to the standard operating procedure. In total, 271 measurements were performed with an average level of 79.0 ± 46.0 mg/L. Seventy-one piperacillin levels exceeded 100 mg/L and six levels were lower than 22.5 mg/L. The high-level and the low-level group differed significantly in infection laboratory parameters (CRP (mg/dL) 20.18 ± 11.71 vs. 5.75 ± 5.33) and renal function [glomerular filtration rate (mL/min/1.75 m2) 40.85 ± 26.74 vs. 120.50 ± 70.48]. Conclusions: Piperacillin levels are unpredictable in critically ill patients. TDM during piperacillin/tazobactam therapy is highly recommended for all patients. Although our implementation strategy was effective, further strategies implemented into the daily clinical workflow might support the health care staff and increase the clinicians' alertness.
Herz-Kreislauf-Erkrankungen stellen weiterhin die Todesursache Nummer eins in Deutschland dar, welche hauptsächlich durch Atherosklerose verursacht werden. Als ein Prädiktor der atherosklerotischen Plaqueentwicklung wird die Wandschubspannung (WSS) diskutiert. Ziel dieser Arbeit war es daher, anhand von Flussphantomen und C57bl/6 Mäusen eine 2D-Gradientenecho-Bildgebungsmethode mit einer 3D-Phasenkontrast-Flusskodierung zu optimieren und anschließend eine longitudinale Kleintierstudie mit ApoE-/- Mäusen durchzuführen, um den Zusammenhang der WSS und der atherosklerotischen Plaqueentwicklung näher zu untersuchen. Zunächst wurden Flussphantome mit einem Schlauchdurchmesser von 4 mm und 1 mm zur Optimierung der Messmethode verwendet. Anschließend wurde die Messmethode weiter angepasst, um in vivo Messungen an C57bl/6 Mäusen durchführen zu können. Nach erfolgter Optimierung wurde eine longitudinale Kleintierstudie mit zwei verschiedenen Diäten, Western Diät und Chow Diät, durchgeführt. Im Rahmen der Studie erfolgten nach einer, acht und zwölf Wochen MR-Messungen sowie histologische Analysen. Es konnte gezeigt werden, dass die Wandschubspannung in Mäusen bei 17,6 Tesla quantifiziert werden kann. Es zeigte sich eine Tendenz, dass Plaqueformationen mit einer höheren Wandschubspannung einhergehen.
Current systemic treatment options for patients with adrenocortical carcinomas (ACCs) are far from being satisfactory. DNA damage/repair mechanisms, which involve, e.g., ataxia-telangiectasia-mutated (ATM) and ataxia-telangiectasia/Rad3-related (ATR) protein signaling or ribonucleotide reductase subunits M1/M2 (RRM1/RRM2)-encoded ribonucleotide reductase (RNR) activation, commonly contribute to drug resistance. Moreover, the regulation of RRM2b, the p53-induced alternative to RRM2, is of unclear importance for ACC. Upon extensive drug screening, including a large panel of chemotherapies and molecular targeted inhibitors, we provide strong evidence for the anti-tumoral efficacy of combined gemcitabine (G) and cisplatin (C) treatment against the adrenocortical cell lines NCI-H295R and MUC-1. However, accompanying induction of RRM1, RRM2, and RRM2b expression also indicated developing G resistance, a frequent side effect in clinical patient care. Interestingly, this effect was partially reversed upon addition of C. We confirmed our findings for RRM2 protein, RNR-dependent dATP levels, and modulations of related ATM/ATR signaling. Finally, we screened for complementing inhibitors of the DNA damage/repair system targeting RNR, Wee1, CHK1/2, ATR, and ATM. Notably, the combination of G, C, and the dual RRM1/RRM2 inhibitor COH29 resulted in previously unreached total cell killing. In summary, we provide evidence that RNR-modulating therapies might represent a new therapeutic option for ACC.